Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06946550 · ClinicalTrials.gov registry record · NA
Non-Ablative Laser to Treat Scarring Alopecia With Hair Follicle Gene Expression Analysis
A NA study of Scarring Alopecia, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06946550: Recruiting NA study of Scarring Alopecia, sponsored by Montefiore Medical Center.
NCT06946550 is a NA study of Scarring Alopecia that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06946550, a NA study of Scarring Alopecia, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the effectiveness of a non-ablative 1470 nm laser in treating scarring alopecia in adults. The study will also investigate the biochemical molecular pathways involved in laser therapy by analyzing hair follicle gene expression before and after laser treatment. The main questions it aims to answer are: 1. Does a non-ablative laser work to effectively treat scarring alopecia? 2. What molecular pathways are associated with the laser's effects on hair follicles in scarring alopecia? Participants with scarring alopecia will: * Receive 3 laser treatments, spaced 1 month apart (Month 1, Month 2, Month 3), and attend 5 follow-up visits (Month 4, Month 6, Month 9, Month 12 and Month 15) * Have hair follicle samples collected via hair plucking of 10 hairs prior to the start and 1-month post-completion of laser treatments for gene expression analysis of inflammatory and fibrosis pathways implicated in scarring alopecia. Hair samples will be de-identified and kept anonymous. * Fill out questionnaires at each visit * Keep a diary of any side effects from laser treatments
Primary Outcome
A clinician will answer the following question after evaluating baseline photos and current photos (at each specified point in time). Please choose the option that better represents the change in hair growth in the treatment area. The options will be as follows: -3 = Greatly worsened -2 = Moderately worsened -1 = Slightly worsened 0 = No change 1 = Slightly worsened 2 = Moderately improved 3 = Greatly improved. Higher scores will be associated with improved hair growth in treatment area as ass
Conditions Studied
Interventions
- DEVICE 1470nm non-ablative fractional laser
Study Locations (1)
New York
- Montefiore Einstein Advanced Care - Elmsford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-12-09 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT06946550 shows while recruiting
NCT06946550 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Scarring Alopecia appearing as the primary indexed condition, and to 1 intervention - of which 1470nm non-ablative fractional laser is the first listed.
NCT06946550 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06946550 about?
NCT06946550 is a clinical study titled "Non-Ablative Laser to Treat Scarring Alopecia With Hair Follicle Gene Expression Analysis". The goal of this clinical trial is to evaluate the effectiveness of a non-ablative 1470 nm laser in treating scarring alopecia in adults. The study will also investigate the biochemical molecular pathways involved in laser therapy by analyzing hair follicle gene expression before and after laser tre...
What is the current status of trial NCT06946550?
This trial is currently recruiting. It is a NA study. The enrollment target is 5 participants. The study started on 2025-12-09. Estimated completion is 2027-12.
What conditions does trial NCT06946550 study?
This clinical trial studies the following conditions: Scarring Alopecia.
What interventions are being tested in trial NCT06946550?
The interventions under investigation include: 1470nm non-ablative fractional laser (DEVICE).
Who is sponsoring clinical trial NCT06946550?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06946550 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scarring Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06946550's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI